ANDA 211253, held by Perrigo Pharma Intl. Diclofenac Sodium.
As of Nov 16, 2026, ANDA 211253 (Diclofenac Sodium), held by Perrigo Pharma Intl, was first approved by FDA on May 16, 2019, with 5 approved supplements and 0 published complete response letters.
Uses for the temporary relief of arthritis pain ONLY in the following areas: hand, wrist, elbow (upper body areas) foot, ankle, knee (lower body areas) this product may take up to 7 days to work for arthritis pain; it is not for immediate relief. If no pain relief in 7 days, stop use.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 16, 2019 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Diclofenac Sodium1% · gel;topical | Diclofenac Sodium | OTC |
| Oct 23, 2026 | Supplement 20Manufacturing | Approved | None posted |
| Sep 28, 2022 | Supplement 14Manufacturing | Approved | None posted |
| Oct 23, 2020 | Supplement 10Manufacturing | Approved | None posted |
| Oct 23, 2020 | Supplement 7Manufacturing | Approved | None posted |
| Apr 1, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| May 16, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters